The Effects of Luo-Bu-Fu-Ke-Bi-RI Pill

Climacteric Syndrome Clinical Trial

Official title:

The Effects of Luo-Bu-Fu-Ke-Bi-RI Pill

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05846698
• Other study ID #: 2021-375
• Status: Completed
• Start date: July 1, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: August 2023
• Source: First Affiliated Hospital of Chongqing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To investigate the effect of LBFKBRP on climacteric syndrome in women and explore its therapeutic mechanism.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 276
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 41 Years to 60 Years
• Eligibility: Clinical diagnosis of climacteric syndrome

Related Conditions & MeSH terms

• Climacteric Syndrome

Intervention

Drug:
• Luo-Bu-Fu-Ke-Bi-RI Pill
10 pills twice daily
• tibolone
2.5 mg once daily

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Guoqing Zhou

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sex hormone		3 month